Posts

Posted on

SOS Ltd. Enters Framework Agreement with Leibodong Hydropower Station in Hejiang , Luzhou City, Sichuan, to Secure Cheap and Renewable Electricity for its Cloud Crypto Mining Center

PR Newswire

QINGDAO, China, Feb. 5, 2021 /PRNewswire/ — SOS Limited (NYSE: SOS) (the “Company” or “SOS”) announced today that it has entered the framework agreement with Leibodong Hydropower Station (“Leibodong”) in Hejiang, Luzhou, Sichuan Province, where hydropower resources are much richer and electricity prices much lower than the rest part of China. Pursuant to the agreement, Leibodong will supply SOS with electricity to its cloud crypto mining and big data center.

Leibodong is located in Dazuoba village, Fubao Town, Hejiang County, Luzhou, Sichuan Province. It is a level three cascade hydropower station of Dacao River Basin of Tang River, the first-level tributary of the upper Yangtze River. The normal water level of Leibodong is 560m, with the function of daily adjustments. Its adjustment capacity is 1.57 million m3. The actual installed capacity of the power station is 25000 KW, the average annual power generation is 99.8 million KW / h.

Pursuant to the agreement, Leibodong will supply electricity to a cloud crypto mining center to be built by SOS for a price between 0.22-0.38kW/h. The parties will enter into definitive agreement with respect to the price and other terms and conditions contemplated by the framework agreement. SOS expects the first shipment of crypto mining machine will be installed on or about Feb. 14, 2021. 

SOS Chairman Yandai Wang commented, “one of the key success factors for cloud crypto mining is to secure cheap power in regions with rich renewable energy resources,. Southwest China, such as Sichuan province, is one of such regions. SOS will continue to search for cheap and sustainable electricity to execute its aspiring cloud crypto mining strategy.”   

About SOS Limited

SOS Limited, through its operating subsidiary, SOS Information Technology Co., Ltd. (“SOS”) is a high-technology company providing a wide range of services to its corporate and individual members, including marketing data, technology and solutions for emergency rescue services. SOS transforms digital technology into data-driven operations through the research and development of big data, cloud computing, Internet of Things, blockchain and artificial intelligence.

We have created a SOS cloud emergency rescue service software as a service (SaaS) platform with three major product categories: basic cloud, cooperative cloud, and information. This system provides innovative marketing solutions to clients such as insurance companies, financial institutions, medical institutions, healthcare providers, auto manufacturers, security providers, senior living assistance providers, and other service providers in the emergency rescue services industry.

SOS has obtained a national high-tech enterprise certification and the title of “big data star enterprise,” awarded by Gui’an New District Government. Staying on the forefront of digital technology innovation, the Company has registered 99 software copyrights and 2 patents. For more information, please visit: http://www.sosyun.com/ 

Forward-Looking Statements

Certain statements made herein are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include timing of the proposed transaction; the business plans, objectives, expectations and intentions of the parties;, SOS’s estimated and future results of operations, business strategies, competitive position, industry environment and potential growth opportunities market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our product offering, product pricing, timing of product launches; management’s expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans and etc. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. SOS may not realize its expectations, and its beliefs may not prove correct. Due to known and unknown risks, our actual results may differ materially from our expectations or projections. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Additional information concerning these and other factors that may impact our expectations and projections can be found in our periodic filings with the SEC, including our Annual Report on Form 20-F for the fiscal year endedDecember 31, 2019. SOS’s SEC filings are available publicly on the SEC’s website at www.sec.gov. SOS disclaims any obligation to update the forward-looking statements, whether as a result of new information, future events or otherwise.

Cision View original content:http://www.prnewswire.com/news-releases/sos-ltd-enters-framework-agreement-with-leibodong-hydropower-station-in-hejiang–luzhou-city-sichuan-to-secure-cheap-and-renewable-electricity-for-its-cloud-crypto-mining-center-301222986.html

SOURCE SOS Limited

Posted on

DTE Energy schedules full year 2020 earnings release, conference call

Detroit, Feb. 05, 2021 (GLOBE NEWSWIRE) — DETROIT, Feb. 5, 2021 – DTE Energy (NYSE:DTE) will announce its full year 2020 earnings before the market opens Friday, February 19, 2021.

The company will conduct a conference call to discuss earnings results at 9 a.m. ET the same day.

Investors, the news media and the public may listen to a live internet broadcast of the call at dteenergy.com/investors. The telephone dial-in number in the U.S. and Canada toll free is: (833) 968-2209 or international toll: (778) 560-2895. The passcode is 3974206. The webcast will be archived on the DTE Energy website at dteenergy.com/investors.

About DTE Energy 

DTE Energy (NYSE: DTE) is a Detroit-based diversified energy company involved in the development and management of energy-related businesses and services nationwide. Its operating units include an electric company serving 2.2 million customers in Southeast Michigan and a natural gas company serving 1.3 million customers in Michigan. The DTE portfolio includes energy businesses focused on power and industrial projects; renewable natural gas; natural gas pipelines, gathering and storage; and energy marketing and trading. As an environmental leader, DTE utility operations will reduce carbon dioxide and methane emissions by more than 80 percent by 2040 to produce cleaner energy while keeping it safe, reliable and affordable. DTE Electric and Gas aspire to achieve net zero carbon and greenhouse gas emissions by 2050. DTE is committed to serving with its energy through volunteerism, education and employment initiatives, philanthropy and economic progress. Information about DTE is available at dteenergy.com, empoweringmichigan.com, twitter.com/dte_energy and facebook.com. 



Pete Ternes
DTE Energy
313.235.5555

Barbara Tuckfield
DTE Energy
313.235.1018

John Dermody
DTE Energy
313.235.8750

Posted on

Celltrion’s COVID-19 Treatment Candidate Receives Korean MFDS Conditional Marketing Authorisation

Celltrion’s COVID-19 Treatment Candidate Receives Korean MFDS Conditional Marketing Authorisation

  • Regdanvimab (CT-P59) receives conditional marketing authorisation from the Korean Ministry of Food and Drug Safety (MFDS); first anti-COVID-19 monoclonal antibody treatment to be approved in Korea
  • CT-P59 is authorised for the treatment of adult patients aged 60 and over, or with at least one underlying medical condition, with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID-19
  • Celltrion is under discussion with the European Medicines Agency (EMA) for Conditional Marketing Authorisation (CMA) and with the U.S. FDA for Emergency Use Authorisation (EUA)
  • The global Phase III clinical trial is on track and the trial is expected to enrol 1,172 patients with mild-to-moderate symptoms of COVID-19

INCHEON, Korea–(BUSINESS WIRE)–
Celltrion Group today announced that the Korean Ministry of Food and Drug Safety (MFDS) granted a Conditional Marketing Authorisation (CMA) for the emergency use of Regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment candidate. The CMA allows for emergency use of CT-P59 in adult patients aged 60 years and over, or with at least one underlying medical condition (cardiovascular, chronic respiratory disease, diabetes, high blood pressure) with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID-19.

The CMA is based on Part 1 of the Phase II/III trial which showed;

  • Patients treated with CT-P59 reporting a significantly reduced risk of COVID-19 related hospitalization and oxygenation up to Day 28
  • Progression rates to severe COVID-19 were reduced by 54% for patients with mild-to-moderate symptoms and 68% for moderate patients aged 50 years and over
  • A significantly shortened time to clinical recovery in CT-P59 treated patients (40 mg/kg) ranging from 3.4 to 6.4 days quicker compared with placebo.

“With the pandemic still raging in Korea, we believe today’s Conditional Marketing Authorisation of Regdanvimab marks an important milestone in the fight against COVID-19” said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. “Patients with COVID-19 in Korea now have access to a therapy according to the authorised indications early in the course of their infection. We remain committed to closely working with the regulatory agencies worldwide including the U.S. FDA and the European Medicines Agency (EMA) to ensure that patients around the world have access to safe and effective treatment against COVID-19 as in the case of Korea.”

A global Phase III clinical trial is currently recruiting and expected to enrol 1,172 patients with mild-to-moderate symptoms of COVID-19 in more than 10 global sites to evaluate efficacy and safety results of CT-P59. Celltrion is set to demonstrate clinical efficacy against COVID-19 in both UK and South African variants and the results to be expected in the coming days.

– ENDS –

Notes to Editors:

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us.

About CT-P59 (Regdanvimab)

CT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus. The mutated G-variant strain (D614G variant) was later identified and confirmed to be inactivated by CT-P59. In pre-clinical data the treatment candidate demonstrated a 100-fold reduction in viral load of SARS-CoV-2, as well as a reduction in lung inflammation. Results from the global Phase I clinical trial of CT-P59 demonstrated promising safety, tolerability, antiviral effect and efficacy profile in patients with mild symptoms of COVID-19.1

FORWARD LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.

These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare’s management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

References

1 Celltrion Data on file

For further information please contact:

Sophia Eminson

[email protected]

+44 (0) 7751 116252

Donna Curran

[email protected]

+44 (0) 7984 550312

KEYWORDS: Asia Pacific South Korea

INDUSTRY KEYWORDS: Health Infectious Diseases Clinical Trials Research Pharmaceutical Science

MEDIA:

Logo
Logo
Posted on

Oncocyte Announces Pricing of $35 Million Public Offering of Common Stock

IRVINE, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) — Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it has priced the previously announced underwritten public offering of 7,780,000 shares of its common stock, at a public offering price of $4.50 per share. The gross proceeds to the Company from this offering are expected to be approximately $35.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. The offering is expected to close on or about February 9, 2021, subject to satisfaction of customary closing conditions. The Company has granted the underwriters a 30-day option to purchase up to an additional 1,167,000 shares of its common stock at the public offering price.

Piper Sandler & Co. is acting as Sole Book-Runner for the offering. BTIG, LLC and Needham & Company are acting as Co-Lead Managers.

Oncocyte intends to use net proceeds from the offering to promote commercialization of its lead diagnostic test DetermaRx™; to complete development of DetermaIO™; and for development of future tests in its pipeline, including the CNI Monitor test that Oncocyte expects to acquire through a merger with Chronix Biomedical, Inc. Proceeds may also be used for pending acquisitions and post-acquisition obligations related to the Chronix merger, the purchase of the outstanding shares of Razor Genomics, Inc. common stock, and the earlier acquisition of Insight Genetics, Inc. Net proceeds not used for the foregoing purposes may be used for general corporate and working capital purposes and to invest in or acquire businesses or technologies that the Company believes are complementary to its business, although the Company has no other binding agreements to acquire any such business or technology.

The offering is being made pursuant to a “shelf” registration statement on Form S-3 (File No. 333-231980) that became effective with the Securities and Exchange Commission (“SEC”) on June 18, 2019, the base prospectus contained therein and a prospectus supplement. A preliminary prospectus supplement and accompanying base prospectus relating to the offering and the shares of common stock being offered has been filed with the SEC. Before you invest, you should read the prospectus in the registration statement, the preliminary prospectus supplement, and other documents the Company has filed with the SEC for more complete information about the Company and this offering. Copies of the registration statement, the preliminary prospectus supplement and accompanying base prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or, when available, by contacting: Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation, or sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful.

About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company’s tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte recently launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. To complement DetermaIO, the company anticipates launching DetermaTx™, a test to assess mutational status of a tumor to help identify the appropriate targeted therapy, in the second half of 2021. The Company also continues with the development of DetermaMx™ as the company seeks to expand into the blood-based monitoring market. Oncocyte’s pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

DetermaRx, DetermaIO, DetermaMx, and DetermaTx are trademarks of Oncocyte Corporation. Therasure is a trademark of Chronix Biomedical Inc.

Oncocyte Forward Looking Statements

Oncocyte cautions you that this press release contains forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the offering and use of proceeds, the potential impact of COVID-19 on our or any distributor’s financial and operational results, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of our third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to our or any distributor’s supply chain, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, and the need to obtain third party reimbursement for patients’ use of any diagnostic tests we commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, greater than estimated allocations of resources to develop and commercialize technologies, or failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact

Bob Yedid
LifeSci Advisors, LLC
646-597-6989
[email protected]

Media Contact

Cait Williamson, Ph.D.
LifeSci Communications, LLC
656-751-4366
[email protected]



Posted on

Newman-Dailey Resort Properties Shares the Love from Destin Vacations for Valentine’s Day

For every Valentine’s stay booked, Newman-Dailey will donate $14 to Food for Thought to fight food insecurity in South Walton and Destin, Florida

Destin, Fla., Feb. 05, 2021 (GLOBE NEWSWIRE) — Florida’s beaches are recognized among the most romantic places in the world. It is easy to see why love flourishes when couples are immersed in a scenic setting with soft sand under foot and shimmering waters for as far as the eye can see. With a diverse collection of cozy vacation rental homes and condominiums along Florida’s Emerald Coast, Newman-Dailey Resort Properties is welcoming beach lovers for a romantic getaway that will share the love with local students. For each Valentine’s stay booked to “Share the Love”, Newman-Dailey will donate $14 to Food for Thought, a local organization helping to fight food insecurity among students in Destin and South Walton.

“We know that a romantic escape to the beach to relax and reconnect ignites love and we wanted to share this love with our local community,” said Jeanne Dailey, founder and CEO of Newman-Dailey Resort Properties. “We have been supporting Food for Thought over the years and the impact they are making with local students by fighting hunger and food insecurity is incredible. Guests can make an even greater impact by donating unopened food items while they are here and we’ll deliver them to Food for Thought. And as an added bonus, it is easy to make it a long weekend since President’s Day is Monday!”

With many scenic settings and secluded spots in state parks and along the shore, the Emerald Coast is an ideal place to get happily lost in love. For active couples, there is a variety of romantic Destin activities to help create memories that will last a lifetime. In addition, Newman-Dailey’s Be Rewarded program includes free movie rentals and discounts to area restaurants and attractions. 

A Valentine’s Day getaway is easily enhanced by planning a romantic meal at one of the dozens of award-winning Destin restaurants. For a special experience, SunQuest Cruise’s Solaris yacht features a special Valentine’s Dinner Cruise as well as Valentine’s Day Brunch. Or for couples who want to be pampered, The Salamander Spa offers couples massages as well as romantic dining at the Primrose Restaurant.

Food For Thought is a 501(c)(3) not-for-profit organization in Florida, that works to fight the negative impacts of child hunger in the lives of Food Insecure children in grades K-12. Their goal is to support a child’s development and educational experience by bridging the gap between school meals and providing food for weekends, holiday breaks, and summer.  

Voted the “Best Vacation Rental Company” along the Emerald Coast by readers of Emerald Coast Magazine, Newman-Dailey Resort Properties offers a vast selection of Destin vacation rental homes and condominiums along the beaches of South Walton and Destin, Florida. From Gulf-front condominiums at Jade East in Destin to private beach homes in Crystal Beach to luxury condominiums at Sanctuary at Redfish on Highway 30-A in Blue Mountain Beach, Newman-Dailey’s premier vacation rentals provide a comfortable home away from home for a Valentine’s Day beach escape. Use promo code: SPREADLOVE to ensure a donation is made on our behalf to Food for Thought. Learn more at DestinVacation.com or call 800-225-7652.

###

About Newman-Dailey Resort Properties, Inc.

Based in Miramar Beach, Newman-Dailey Resort Properties is a premier real estate company, offering property management, vacation rental, real estate sales, long term leasing and association management services in Northwest Florida. Founded in 1985, Newman-Dailey has been welcoming guests to the beaches of South Walton and Destin, Fla. for more than 30 years. Recognized among Florida Trend’s Best Companies to Work for in Florida, Newman-Dailey was also voted the “Best Vacation Rental Company” and “Best Property Management Company” by the readers of Emerald Coast Magazine. Newman-Dailey’s Real Estate Division is consistently listed among the top 10 percent of real estate companies along the Emerald Coast for sales.  For more information, call 850.837.1071 or visit online at NewmanDailey.com.

Attachments 



Tracy Louthain
Newman-Dailey Resort Properties
8508371071
[email protected]

Posted on

Apache Corporation Declares Cash Dividend on Common Shares

HOUSTON, Feb. 05, 2021 (GLOBE NEWSWIRE) — The board of directors of Apache Corporation (Nasdaq: APA) has declared a regular cash dividend on the company’s common shares.

The dividend on common shares is payable May 21, 2021, to stockholders of record on Apr. 22, 2021, at a rate of 2.5 cents per share on the corporation’s common stock.

About Apache

Apache Corporation is an oil and gas exploration and production company with operations in the United States, Egypt and the United Kingdom and exploration activities offshore Suriname. Apache posts announcements, operational updates, investor information and press releases on its website, www.apachecorp.com. Specific information concerning Suriname, ESG performance and other investor-related topics are posted at investor.apachecorp.com.

Contacts

Media: (713) 296-7276   Phil West
Investor: (281) 302-2286   Gary Clark
   
Website: www.apachecorp.com 

APA-F

 



Posted on

Isoray To Announce Second Quarter Fiscal 2021 Financial Results on February 9, 2021

Conference Call is Tuesday, February 9, 2021 at 4:30 p.m. ET/1:30 p.m. PT

RICHLAND, Wash., Feb. 05, 2021 (GLOBE NEWSWIRE) —  Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the second quarter fiscal year 2021 ended December 31, 2020 on Tuesday, February 9, 2021, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the second quarter fiscal year 2021 after the close of the U.S. stock markets on February 9, 2021.

To listen to the conference call, please dial 877-407-8035. For callers outside the U.S., please dial 201-689-8035.

The conference call will be simultaneously webcast and can be accessed at  https://www.webcaster4.com/Webcast/Page/2199/39694. The webcast will be available until May 9, 2021 following the conference call.

About Isoray

Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook and follow us on Twitter @Isoray. 



Contact
Investor Relations: Mark Levin (501) 255-1910
Media and Public Relations: Sharon Schultz (302) 539-3747

Posted on

U.S. Navy Partners with Ameresco for $173 Million Cleantech Energy Project at Norfolk Naval Shipyard

U.S. Navy Partners with Ameresco for $173 Million Cleantech Energy Project at Norfolk Naval Shipyard

 

Ameresco to implement advanced energy solutions that will maximize reliability and resiliency at Virginia naval shipyard

FRAMINGHAM, Mass.–(BUSINESS WIRE)–Ameresco, Inc., (NYSE: AMRC), a leading energy efficiency and renewable energy company, today announced that the U.S. Navy and the Ameresco Federal Solutions team are breaking ground to expand on-site generation, strengthen reliability, and enhance resiliency at Norfolk Naval Shipyard (NNSY) in Portsmouth, Virginia. This $173 million energy savings performance contract (ESPC) builds on Ameresco’s two decades of support to the NNSY mission to repair, overhaul, and refuel the most technologically advanced warships in the world. Because ESPCs leverage the guaranteed savings the projects generate to secure third-party financing, the Navy will not have to contribute up-front funding during the project’s implementation phase.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210205005086/en/

U.S. Navy and Ameresco team members broke ground on the $173 million cleantech energy project at Norfolk Naval Shipyard.

U.S. Navy and Ameresco team members broke ground on the $173 million cleantech energy project at Norfolk Naval Shipyard.

Ameresco is now preparing to construct a new 19-megawatt (MW) combined heat and power (CHP) plant, a 3MW battery energy storage system, and a microgrid control system that will provide the site with long-term energy security while reducing the electricity imported from the grid by 68 percent. As part of this modernization effort, Ameresco will refurbish existing backup power assets, integrate them into the microgrid, and upgrade the electric distribution system to provide redundant sources of supply.

This project also features a new industrial wastewater treatment plant (IWTP), a critical element of shipyard infrastructure that Ameresco has already begun to build. The effective treatment of contaminated wastewater that the site’s ship repair activities produce is critical to NNSY’s mission of ensuring that ships can return to service on schedule. Tasked by the Navy with assessing potential industrial process improvements, Ameresco developed a solution that produces enough savings from recycling water within the plant, enclosing exposed system components, and reducing operating costs to pay for the complete replacement of the site’s 40-year-old IWTP.

“This project, which features both a new industrial water treatment plant and the integration of a new CHP plant and battery storage within a microgrid control system, will deliver long-term efficiency, reliability, and resiliency in support of the NNSY mission,” said Nicole Bulgarino, executive vice president and general manager of Federal Solutions at Ameresco. “We value our long-term partnership with the U.S. Navy and take seriously our responsibility to help advance their mission and support the environment through the deployment of clean energy technology.”

After construction is completed in 2022, Ameresco will operate and maintain the CHP plant, IWTP, and microgrid until January 2044. Each measure is designed to operate in compliance with relevant Department of Defense and Navy cybersecurity requirements. Over the course of the 22-year performance period following construction, the project will generate more than $411 million in guaranteed cost savings.

About Norfolk Naval Shipyard

Norfolk Naval Shipyard (NNSY) in Portsmouth, Va. serves as the Navy’s main East Coast repair, overhaul and modernization facility. NNSY is one of Naval Sea Systems Command’s four public shipyards that play a major role in maintaining America’s fleet and providing a wartime surge capability to keep the nation’s ships ready for combat.

About Ameresco, Inc.

Founded in 2000, Ameresco, Inc. (NYSE:AMRC) is a leading independent provider of comprehensive services, energy efficiency, infrastructure upgrades, asset sustainability and renewable energy solutions for businesses and organizations throughout North America and Europe. Ameresco’s sustainability services include upgrades to a facility’s energy infrastructure and the development, construction and operation of renewable energy plants. Ameresco has successfully completed energy saving, environmentally responsible projects with Federal, state and local governments, healthcare and educational institutions, housing authorities, and commercial and industrial customers. With its corporate headquarters in Framingham, MA, Ameresco has more than 1,000 employees providing local expertise in the United States, Canada, and the United Kingdom. For more information, visit www.ameresco.com.

The announcement of a customer’s entry into a project contract is not necessarily indicative of the timing or amount of revenue from such contract, of the company’s overall revenue for any particular period or of trends in the company’s overall total project backlog. This project was included in our previously reported contracted backlog as of September 30, 2020.

Ameresco:

Leila Dillon

508-661-2264

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Maritime Defense Transport Alternative Energy Energy Contracts

MEDIA:

Logo
Logo
Photo
Photo
U.S. Navy and Ameresco team members broke ground on the $173 million cleantech energy project at Norfolk Naval Shipyard.
Posted on

Mydecine Innovations Group Files Amended and Restated Financial Statements

Mydecine Innovations Group Files Amended and Restated Financial Statements

VANCOUVER, British Columbia–(BUSINESS WIRE)–
Mydecine Innovations Group Inc. (the “Company”) (CSE:MYCO | OTC:MYCOF) (FSE: 0NFA) announces it has filed amended and restated unaudited condensed interim consolidated financial statements for the nine-month period ended September 30, 2020 (the “Restated Statements”) and related amended and restated management discussion and analysis (“RestatedMD&A”and together with the Restated Statements, the “Restated Documents”).

Subsequent to the filing of the Company’s condensed interim consolidated financial statements for the nine months ended September 30, 2020 (the “Original Statements”) on November 30, 2020, management of the Company engaged its auditors to review the Original Statements. Based on discussions with its auditors in connection with such review, management determined that certain adjustments are required in the Restated Documents resulting in a decrease in total assets of $493,214, an increase in total liabilities of $1,830,594 and a decrease in total shareholders’ equity of $2,323,808, in each case, as at September 30, 2020 and an increase in total net loss by $2,282,519 for the nine months ended on September 30, 2020.

The adjustments to the Financial Statements include:

  • The Company increased its non-cash contingent consideration and derivative liability as at September 30, 2020 by $1,857,713. In connection with the acquisition of NeuroPharm Inc. (“NeuroPharm”) on August 28, 2020 and Mindleap Health Inc. on August 20, 2020, the Company granted to the vendors certain rights (the “Rights”) to receive additional Shares if the trading price of the Shares decreased in certain circumstances. The Restated Financials accounted for the increase in contingent consideration and derivative liability related to the Rights as a result of the decrease in the trading price of the Shares from the applicable date of closing of each such acquisition to September 30, 2020.
  • The Company increased the value of the non-cash consideration paid on August 28, 2020 to acquire NeuroPharm by $616,362. The Restated Statements state that, of the 9,000,000 Shares issued by the Company as consideration, 4,244,121 Shares are subject to a 24-month escrow, whereas the Original Statements state that, of the 9,000,000 Shares issued by the Company as consideration, 6,750,000 Shares are subject to an 18-month escrow. Such change resulted in an increase in the consideration paid to acquire NeuroPharm of $616,362 and an increase in consideration paid in excess of identifiable assets of $616,362.
  • The Company decreased the aggregate value of the 4,500,000 common shares of the Company (“Share”) issued as non-cash consideration on April 27, 2020 to acquire 50% of Alternative Distribution Company LLC (formerly Levee Street Holdings, LLC) by $270,000. It was determined that such Shares should be valued at $0.05 per Share, being the issue price under the Company’s private placement dated May 7, 2020, whereas they were valued at $0.11 per Share in the Original Statements. The resulting adjustment resulted in a decrease in distribution expense of $270,000.
  • The Company decreased the value of the non-cash share-based compensation for the nine months ended September 30, 2020 by $370,063 and increased the aggregate fair value of finder warrants and agent’s compensation options by $701,113 for the nine months ended September 30, 2020, in both cases, due to input differences and recalculations using the Black-Scholes Option Pricing Model.
  • The Company has written off the inventory of two of its subsidiaries, Tealief Brands, LLC and Relyfe Brands, LLC, valued at $458,921 in the Original Statements, since the Company no longer intends to sell such inventory.

The changes discussed above are described in Note 17 to the Restated Statements, as filed on SEDAR.

The Original Statements and the original management’s discussion and analysis for the financial periods were originally filed by the Company on SEDAR on November 30, 2020. The Restated Documents replaces and supersedes the Original Statements and related management’s discussion and analysis.

There have been no other changes. All amounts are expressed in Canadian dollars unless otherwise noted.

About Mydecine Innovations Group

Mydecine Innovations Group™ is a life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing. The company’s world renowned medical and scientific advisory board is progressing a robust R&D pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, extract, and analyze natural and synthetic psychedelic compounds with full government approval through Health Canada. Mydecine’s portfolio companies Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ position the company at the forefront of disruptive modern medicine.

Learn more at: https://www.mydecine.com/ and follow us on Facebook, Twitter, and Instagram.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

Forward-looking Information Statement

This news release may contain certain “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian and United States securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target, “plan”, “forecast”, “may”, “schedule” and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to the anticipated timing for the filing of the Restated Documents, and other factors or information. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations.

On behalf of the Board of Directors

MYDECINE INNOVATIONS GROUP INC.

Joshua Bartch

Chief Executive Officer

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Biotechnology Alternative Medicine Professional Services Health General Health Pharmaceutical Mental Health Other Science Research Science Finance

MEDIA:

Logo
Logo
Posted on

EHang to Demonstrate Medical Air Mobility via Participation in EU-supported SAFIR-Med Project

GUANGZHOU, China, Feb. 05, 2021 (GLOBE NEWSWIRE) — EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (AAV) technology platform company, today announced its participation as the only passenger eVTOL partner in the SAFIR-Med project. SAFIR-Med, which stands for “Safe and Flexible Integration of Advanced U-Space Services for Medical Air Mobility”, is a research and innovation project to promote the use of unmanned aviation in healthcare systems across the European Union. The project aims to ensure that healthcare is of high quality and accessible to all citizens of the EU. The project has selected 17 renowned partners from 8 countries and is supported by 8 cross-industry advisory board members including the European Aviation Safety Agency (EASA) and The Red Cross. Within two years, the project intends to demonstrate advanced U-Space services enabling the highest possible operational safety level. These include detect-and-avoid as a service, dynamic geofencing and air traffic prioritization rules.

EHang will use EH216, its flagship two-seat passenger-grade AAV, and its Falcon medium-sized AAV to transport medical supplies in urban environment.  The demonstrations will take place in collaboration with healthcare providers like hospitals and medical spaces in the cities of Antwerp (Belgium), Aachen (Germany), Heerlen (the Netherlands) and Maastricht (the Netherlands), leveraging the MAHHL trans-border region. The project results will then be further demonstrated in two additional locations in Europe, namely Athens, Greece and Prague, Czech Republic. Prior to the operational environment demonstrations, a de-risking exercise at the DronePort BVLOS test-facility (Belgium) will take place.

Using its expertise and abundant experience, EHang will help formulate a performance assessment and recommendations report, which will refine the current U-space architecture principles, propose operational procedures and mechanisms for an effective interface between Air Traffic Control (ATC) and U-Space service providers, and suggest a set of Urban Air Mobility (UAM) indicators to complement the existing smart urban mobility indicators used by European cities. The project is among several managed by the SESAR Joint Undertaking in an effort to deliver solutions for U-space, the European Commission’s initiative on the safe and secure integration of drones in European airspace.

Participation in the SAFIR-Med project marks another milestone for EHang in Europe following two major UAM programs, the AMU-LED project supported by the European Union and the Re.Invent Air Mobility initiative launched in the Paris region. Leveraging its past regulatory breakthroughs and comprehensive partnership network, EHang will expand its global flight tour to more cities and showcase its leading AAV products and solutions in various use cases including passenger commuting and emergency medical transport, etc. As the world’s first listed UAM company to achieve global commercialization of its passenger-grade AAVs, EHang is also well positioned to work with all parties to facilitate product innovations and construction of a UAM legal framework in Europe.

About EHang

EHang (Nasdaq: EH) is the world’s leading autonomous aerial vehicle (AAV) technology platform company. Our mission is to make safe, autonomous, and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility (UAM) industry, EHang continues to explore the boundaries of the sky to make flying technologies benefit our life in smart cities. For more information, please visit www.ehang.com.

About SAFIR-Med

The vision of SAFIR-Med project is to demonstrate ways to achieve safe, sustainable, socially accepted and effective urban air mobility, which will contribute to the EU healthcare system, by ensuring that future generations will continue to have access to the best cure and care. Coordinated by the project leading company Helicus, SAFIR-Med includes all value chain actors and stakeholders as either project partners (ANSP/ATC, USSP, Operator, UAS Manufacturers, cities) or advisory board members (governmental agencies including healthcare actors, technology & service providers). The project has received funding from the European Union’s Horizon 2020 research and innovation program under Grant Agreement No 101017701 under the topic “SESAR-VLD2-03-2020 – U-space capabilities and services to enable Urban Air Mobility”.

Learn more about SAFIR-Med: www.safir-med.eu.  

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements. Management has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While they believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond management’s control. These statements involve risks and uncertainties that may cause EHang’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

Media Contact: [email protected]

Investor Contact: [email protected]  

In the U.S.: [email protected]

In China: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/401050aa-9885-4ea2-8088-02bc54128732